Ultragenyx Pharmaceutical
RARE
$27.66
Share price
0.18%
Change (1 day)
-38.86%
Change (1 year)
Categories
Ultragenyx Pharmaceutical (RARE) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : $1.16 Billion USD
According to Ultragenyx Pharmaceutical's latest financial reports the company's total liabilities are $1.16 Billion USD. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Ultragenyx Pharmaceutical - Total liabilities on balance sheet (from 2012 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.24 B | 2.1% |
| 2023-12-31 | $1.21 B | 1.9% |
| 2022-12-31 | $1.19 B | 98.88% |
| 2021-12-31 | $0.59 B | -0.88% |
| 2020-12-31 | $0.60 B | 25.63% |
| 2019-12-31 | $0.48 B | 335.37% |
| 2018-12-31 | $0.11 B | 3.12% |
| 2017-12-31 | $0.10 B | 60.98% |
| 2016-12-31 | $66.65 M | 134.04% |
| 2015-12-31 | $28.47 M | 118.7% |
| 2014-12-31 | $13.02 M | 36.5% |
| 2013-12-31 | $9.54 M | 139.94% |
| 2012-12-31 | $3.97 M | 167.56% |
| 2011-12-31 | $1.48 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | $1.35 B | 16.62% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | $0.59 B | -48.63% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | $0.75 B | -35.36% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | $0.17 B | -84.95% | 🇺🇸 USA |